NCT02962063 2025-09-05Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal CancerMemorial Sloan Kettering Cancer CenterPhase 1/2 Active not recruiting64 enrolled